| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Asociación para Evitar la Ceguera en México |
| Information provided by: | Asociación para Evitar la Ceguera en México |
| ClinicalTrials.gov Identifier: | NCT00600301 |
Purpose
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.
| Condition | Intervention | Phase |
|
Diffuse Diabetic Macular Edema |
Drug: Triamcinolone Acetonide and Bevacizumab |
Phase III |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Edema |
| Drug Information available for: | Bevacizumab Triamcinolone acetonide Triamcinolone Triamcinolone diacetate Triamcinolone hexacetonide |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Eligibility
| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Maximiliano Gordon, MD | 10841400 ext 1171, 1172 | retinamex@yahoo.com |
| Mexico, D.F. | |||||
| Asociacion Para Evitar la Ceguera en Mexico | Recruiting | ||||
| Mexico D.F., D.F., Mexico, 04030 | |||||
| Contact: Maximiliano Gordon, MD 10841400 ext 1171, 1172 retinamex@yahoo.com | |||||
| Asociación para Evitar la Ceguera en México |
| Principal Investigator: | Maximiliano Gordon, MD | APEC |
More Information
| Study ID Numbers: | APEC-OO13 |
| First Received: | June 30, 2006 |
| Last Updated: | January 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00600301 |
| Health Authority: | Mexico: Secretaria de Salud |
|
|
|
|
|
|
